Pharmacological intervention on diabetic retinopathy with PGF - LATANO-2

Status

Active, not recruiting

Phases

Phase 1Phase 3Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2010-022433-29-DK

Enrollment

Registered

2010-08-26

Start date

2010-10-13

Completion date

Unknown

Last updated

2016-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic retinopathy

Interventions

Trade Name: Xalatan Pharmaceutical Form: Eye drops* INN or Proposed INN: LATANOPROST CAS Number: 130209-82-4 Pharmaceutical form of the placebo: Ear drops* Route of administration of the placebo: Conj

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 1 diabetes mellitus Diabetic retinopathy not requiring photocoagulation treatment Age between 20 and 36 years Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Present or previous treatment for glaucoma Retinal disease except for diabetic retinopathy Known cardio-vascular disease Pregnancy

Design outcomes

Primary

Measure	Time frame
Main Objective: To reduce the diameter of retinal arterioles;Secondary Objective: To reduce the development of diabetic retinopathy;Primary end point(s): A reduction in the diameter of retinal arterioles A reduction in the number of diabetic retinopathy lesions	—

Countries

Denmark

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026